高级检索
当前位置: 首页 > 详情页

High TRAF6 Expression Is Associated With Esophageal Carcinoma Recurrence and Prompts Cancer Cell Invasion

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Fudan Univ, Zhongshan Hosp, Dept Internal Med, Shanghai, Peoples R China [2]Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China [3]Hebei Med Univ, Hosp 4, Dept Thorac Surg, 12 Jian Kang Rd, Shijiazhuang 050011, Hebei, Peoples R China [4]Hebei Chest Hosp, Dept Med Affairs, Shijiazhuang 050041, Hebei, Peoples R China
出处:
ISSN:

关键词: Tumor necrosis factor receptor-associated factor 6 (TRAF6) Esophageal cancer (EC) Prognosis Invasion Asparaginyl endopeptidase (AEP) Matrix metalloproteinase (MMP)

摘要:
Esophageal cancer is one of the most common types of cancer, and it has a poor prognosis. The molecular mechanisms of esophageal cancer progression remain largely unknown. In this study, we aimed to investigate the clinical significance and biological function of tumor necrosis factor receptor-associated factor 6 (TRAF6) in esophageal cancer. Expression of TRAF6 in esophageal cancer was examined, and its correlation with clinicopathological factors and patient prognosis was analyzed. A series of functional and mechanism assays were performed to further investigate the function and underlying mechanisms in esophageal cancer. Expression of TRAF6 was highly elevated in esophageal cancer tissues, and patients with high TRAF6 expression have a significantly shorter survival time than those with low TRAF6 expression. Furthermore, loss-of-function experiments showed that knockdown of TRAF6 significantly reduced the migration and invasion abilities of esophageal cancer cells. Moreover, the pro-oncogenic effects of TRAF6 in esophageal cancer were mediated by the upregulation of AEP and MMP2. Altogether, our data suggest that high expression of TRAF6 is significant for esophageal cancer progression, and TRAF6 indicates poor prognosis in esophageal cancer patients, which might be a novel prognostic biomarker or potential therapeutic target in esophageal cancer.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2017]版:
Q3 ONCOLOGY
最新[2024]版:
Q2 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Fudan Univ, Zhongshan Hosp, Dept Internal Med, Shanghai, Peoples R China
共同第一作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号